Author:
Jonsson Marte,Ragnum Harald Bull,Julin Cathinka Halle,Yeramian Andree,Clancy Trevor,Frikstad Kari-Anne Myrum,Seierstad Therese,Stokke Trond,Matias-Guiu Xavier,Ree Anne Hansen,Flatmark Kjersti,Lyng Heidi
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57: 289–300.
2. Bose P, Dai Y, Grant S (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143 (3): 323–336.
3. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ (2006) An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 65: 91–99.
4. Chan N, Milosevic M, Bristow RG (2007) Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol 3: 329–341.
5. Chen S, Sang N (2011) Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol 2011: 197946.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献